Lymphocyte-activation gene 3

Last updated

LAG3
Identifiers
Aliases LAG3 , CD223, lymphocyte activating 3
External IDs OMIM: 153337; MGI: 106588; HomoloGene: 1719; GeneCards: LAG3; OMA:LAG3 - orthologs
Orthologs
SpeciesHumanMouse
Entrez

3902

16768

Ensembl

ENSG00000089692

ENSMUSG00000030124

UniProt

P18627

Q61790

RefSeq (mRNA)

NM_002286

NM_008479

RefSeq (protein)

NP_002277

NP_032505

Location (UCSC) Chr 12: 6.77 – 6.78 Mb Chr 6: 124.88 – 124.89 Mb
PubMed search [3] [4]
Wikidata
View/Edit Human View/Edit Mouse

Lymphocyte-activation gene 3, also known as LAG-3, is a protein which in humans is encoded by the LAG3 gene. [5] LAG3, which was discovered in 1990 [6] and was designated CD223 (cluster of differentiation 223) after the Seventh Human Leucocyte Differentiation Antigen Workshop in 2000, [7] is a cell surface molecule with diverse biological effects on T cell function but overall has an immune inhibitory effect. It is an immune checkpoint receptor and as such is the target of various drug development programs by pharmaceutical companies seeking to develop new treatments for cancer and autoimmune disorders. In soluble form it is also being developed as a cancer drug in its own right. [8]

Contents

Conservation of their respective cytoplasmic tail motifs, CxC/H in the case of CD4 and an ITIM-like motif in the case of LAG-3, supports that competition between CD4 and LAG-3 for binding of kinase LCK is a conserved core part of the jawed vertebrate immune system. CD4 and LAG-3 with opposing functions.png
Conservation of their respective cytoplasmic tail motifs, CxC/H in the case of CD4 and an ITIM-like motif in the case of LAG-3, supports that competition between CD4 and LAG-3 for binding of kinase LCK is a conserved core part of the jawed vertebrate immune system.

LAG-3 is closely related to CD4, [9] with which it shares the ability to bind MHC class II molecules. [10] Although there has been conflicting information on which motifs in the LAG-3 cytoplasmic tail are important for function, [11] [12] [13] evolutionary conversation patterns [14] [15] combined with functional studies [12] [13] imply that the evolutionarily conserved core function of LAG-3 is an inhibitory competition through an immunoreceptor tyrosine-based inhibitory motif (ITIM)–like motif with the activating receptors CD4 or CD8 for binding the kinase LCK. [14]

Gene

The LAG3 gene contains 8 exons. The sequence data, exon/intron organization, and chromosomal localization all indicate a close relationship of LAG3 to CD4. [5] The gene for LAG-3 lies adjacent to the gene for CD4 on human chromosome 12 (12p13) and is approximately 20% identical to the CD4 gene, [16] and this gene organization can already be found in sharks.

Protein

The LAG3 protein, which belongs to immunoglobulin (Ig) superfamily, comprises a 503-amino acid type I transmembrane protein with four extracellular Ig-like domains, designated D1 to D4. When human LAG-3 was cloned in 1990 it was found to have approx. 70% homology with murine LAG3. [6] The homology of pig LAG3 is 78%. [17]

Tissue distribution

LAG-3 is expressed on activated T cells, [18] natural killer cells, [6] B cells [19] and plasmacytoid dendritic cells. [20]

Function

LAG3's main ligand is MHC class II, to which it binds with higher affinity than CD4. [10] The protein negatively regulates cellular proliferation, activation, [21] and homeostasis of T cells, in a similar fashion to CTLA-4 and PD-1 [22] [23] and has been reported to play a role in Treg suppressive function. [24]

Fibrinogen-like protein1 FGL1, a liver-secreted protein, is another (major) LAG3 functional ligand independent of MHC-II. [25]

LAG3 also helps maintain CD8 + T cells in a tolerogenic state [16] and, working with PD-1, helps maintain CD8 exhaustion during chronic viral infection. [26]

LAG3 is known to be involved in the maturation and activation of dendritic cells. [27]

LAG3 has also been implicated in the transmission pathologic α-synuclein in Parkinson's disease [28] [29]

Use as a pharmaceutical and as a drug target

There are three approaches involving LAG3 that are in clinical development.

History

1990 to 1999

LAG3 was discovered in 1990 by Frédéric Triebel (currently Chief Scientific Officer at Immutep) when he headed the cellular immunology group in the Department of Clinical Biology at the Institut Gustave Roussy. [9] An initial characterization of the LAG-3 protein was reported in 1992 showing that it was a ligand for MHC class II antigens [36] while a 1995 paper showed that it bound MHC Class II better than CD4. [10] In 1996 INSERM scientists from Strasbourg showed, in knockout mice that were deficient in both CD4 and LAG-3, that the two proteins were not functionally equivalent. [37] The first characterization of the MHC Class II binding sites on LAG-3 were reported by Triebel's group in 1997. [38] The phenotype of LAG-3 knockout mice, as established by the INSERM Strasbourg group in 1996, demonstrated that LAG-3 was vital for the proper functioning of natural killer cells [39] but in 1998 Triebel, working with LAG-3 antibodies and soluble protein, found that LAG-3 did not define a specific mode of natural killing. [40]

In May 1996, CD4+ T cells that were LAG-3+ were shown to preferentially express IFN-γ, which was up-regulated by IL-12. [41] In 1997, it was demonstrated that IFN-γ production drives LAG-3 expression during the lineage commitment of human naive T cells. [42] In 1998, further research showed that IFN-γ is not required for the expression but rather for the up-regulation of LAG-3. [43] LAG-3 expression on activated human T cells is upregulated by IL-2, IL-7, and IL-12, and its expression may be controlled by CD4 regulatory elements. [44] It was also found that LAG-3 down-modulates T cell proliferation and activation when LAG-3/MHC Class II co-caps with the CD3/TCR complex. [45] This was confirmed in 1999 with co-capping experiments and fluorescence microscopy. [46] In 1999, it was demonstrated that LAG-3 could be used as a cancer vaccine through cancer cell lines transfected with LAG-3. [47]

2000 to 2009.

In 2001, a LAG3-associated protein, called LAP, was identified, which appeared to participate in immune system down-regulation. [48] Also in 2001, LAG3 expression was found on CD8+ tumor-infiltrating lymphocytes, with this LAG3 contributing to APC activation. [49] In August 2002, the first phenotypic analysis of the murine LAG-3 was reported. [50] Molecular analysis in November 2002 demonstrated that the inhibitory function of LAG-3 is performed via the protein's cytoplasmic domain. [11] In 2003, MHC class II signal transduction pathways in human dendritic cells induced by LAG3 were identified. [51] It was also shown that the absence of LAG3 caused no defect in T cell function. [22]

In May 2004, it was shown through LAG3 knockout mice that LAG-3 negatively regulates T cell expansion and controls the size of the memory T cell pool. [23] This was in contrast to earlier *in vitro* work suggesting that LAG-3 was necessary for T cell expansion. [22] Research published in October 2004 identified LAG3's key role in regulatory T cells. [24] In December 2004, it was reported that LAG-3 is cleaved within the D4 transmembrane domain into two fragments that remain membrane-associated: a 54-kDa fragment containing all the extracellular domains, which oligomerizes with full-length LAG-3 (70 kDa) on the cell surface via the D1 domain, and a 16-kDa peptide containing the transmembrane and cytoplasmic domains, which is subsequently released as soluble LAG-3. [52]

In January 2005, it was shown that LAG-3 expression by tumor cells would recruit APCs into the tumor, leading to a Th1 immune response. [53] In March 2005, it was reported that SNPs on LAG3 conferred susceptibility to multiple sclerosis. [54] However, later work found no significant association. [55] In June 2005, it was demonstrated that antibodies to LAG-3 result in T cell expansion, due to increased rounds of cell division that LAG-3 signaling would normally block. [56] In July 2005, it was established that LAG3 expression on B cells is induced by T cells. [19]

In 2006, it was demonstrated that LAG-3 could be used as a biomarker to assess the induction of Th-type responses in recipients of acellular pertussis vaccines. [57]

In April 2007, LAG-3 was shown to participate in Treg-induced upregulation of CCR7 and CXCR4 on dendritic cells, leading to the development of semi-mature dendritic cells with the ability to migrate into lymphoid organs. [58] LAG-3 was also found to play a role in immune privilege in the eye. [59] Later in 2007, it was shown that LAG-3 maintained tolerance to self and tumor antigens through both CD4+ and CD8+ cells, independently of its role on Treg cells. [60]

In 2009, LAG-3 was reported to appear on plasmacytoid dendritic cells. [20] It was also shown to be a marker of Tregs that secrete IL-10. [61]

2010 to 2015.

In 2010, it was shown that LAG3 is an exhaustion marker for CD8+ T cells specific for Lymphocytic choriomeningitis virus, but alone did not significantly contribute to T-cell exhaustion. [62] CD8+ Tumor-infiltrating lymphocytes specific for NY-ESO-1 were found to be negatively regulated by LAG-3 and PD-1 in ovarian cancer. [63] It was reported that most LAG3 is housed intracellularly in multiple domains before rapid translocation to the cell surface, potentially facilitated by the microtubule organizing center and recycling endosomes during T-cell activation. [64] LAG3 was also shown to define a potent regulatory T cell subset that is more frequently observed in cancer patients and expanded at tumor sites. [65] Additionally, SNPs in the LAG3 gene were associated with a higher risk of multiple myeloma. [66]

In 2011, it was reported that when antibodies to CD40L induced tolerance in allogeneic bone marrow transplantation, LAG3 played a role in the mechanism of action in CD8+ cells. [67] It was also shown that the binding of MHC class II molecules on melanoma cells to LAG3 increased resistance to apoptosis, suggesting that antibodies to LAG3 could be relevant in melanoma therapy. [68] Further research demonstrated that LAG3 plays a modulating role in autoimmune diabetes. [69] Additionally, blocking PD-L1 and LAG-3 was identified as a potential therapeutic strategy for Plasmodium infection. [70] In 2012 the St. Jude Children's Research Hospital group showed that LAG-3 and PD-1 synergistically regulate T-cell function in such a way as to allow an anti-tumoral immune response to be blunted. [71] Scientists at Hanyang University in Seoul showed that tetravalent CTLA4-Ig and tetravalent LAG3-Ig could synergistically prevent acute graft-versus-host disease in animal models. [72] In 2013 scientists at the San Raffaele Scientific Institute in Milan showed that LAG3 was a marker of type 1 Tregs. [73]

In 2014, it was shown that LAG engagement could reduce alloreactive T cell responses following bone marrow transplantation. [74] A subset of HIV-specific LAG3(+)CD8(+) T cells was identified, which negatively correlated with plasma viral load. [75] LAG3 expression on plasmacytoid dendritic cells was found to contribute to creating an immune-suppressive environment in melanoma. [76] It was also demonstrated that LAG-3 translocates to the cell surface in activated T cells via its cytoplasmic domain through protein kinase C signaling. [77]

In 2015, it was demonstrated that LAG3 on Tregs works with TGF beta 3 to suppress antibody production. [78] Additionally, research in rhesus macaques showed that Mycobacterium tuberculosis modulates the anti-bacterial immune response through LAG3. [79] Furthermore, it was shown that LAG3 plays a role in the immunosuppressive capacity of Tregs stimulated by Peyer's patch B cells. [80]

Related Research Articles

<span class="mw-page-title-main">Cytotoxic T cell</span> T cell that kills infected, damaged or cancerous cells

A cytotoxic T cell (also known as TC, cytotoxic T lymphocyte, CTL, T-killer cell, cytolytic T cell, CD8+ T-cell or killer T cell) is a T lymphocyte (a type of white blood cell) that kills cancer cells, cells that are infected by intracellular pathogens (such as viruses or bacteria), or cells that are damaged in other ways.

<span class="mw-page-title-main">T helper cell</span> Type of immune cell

The T helper cells (Th cells), also known as CD4+ cells or CD4-positive cells, are a type of T cell that play an important role in the adaptive immune system. They aid the activity of other immune cells by releasing cytokines. They are considered essential in B cell antibody class switching, breaking cross-tolerance in dendritic cells, in the activation and growth of cytotoxic T cells, and in maximizing bactericidal activity of phagocytes such as macrophages and neutrophils. CD4+ cells are mature Th cells that express the surface protein CD4. Genetic variation in regulatory elements expressed by CD4+ cells determines susceptibility to a broad class of autoimmune diseases.

<span class="mw-page-title-main">Major histocompatibility complex</span> Cell surface proteins, part of the acquired immune system

The major histocompatibility complex (MHC) is a large locus on vertebrate DNA containing a set of closely linked polymorphic genes that code for cell surface proteins essential for the adaptive immune system. These cell surface proteins are called MHC molecules.

The regulatory T cells (Tregs or Treg cells), formerly known as suppressor T cells, are a subpopulation of T cells that modulate the immune system, maintain tolerance to self-antigens, and prevent autoimmune disease. Treg cells are immunosuppressive and generally suppress or downregulate induction and proliferation of effector T cells. Treg cells express the biomarkers CD4, FOXP3, and CD25 and are thought to be derived from the same lineage as naïve CD4+ cells. Because effector T cells also express CD4 and CD25, Treg cells are very difficult to effectively discern from effector CD4+, making them difficult to study. Research has found that the cytokine transforming growth factor beta (TGF-β) is essential for Treg cells to differentiate from naïve CD4+ cells and is important in maintaining Treg cell homeostasis.

<span class="mw-page-title-main">CD4</span> Marker on immune cells

In molecular biology, CD4 is a glycoprotein that serves as a co-receptor for the T-cell receptor (TCR). CD4 is found on the surface of immune cells such as helper T cells, monocytes, macrophages, and dendritic cells. It was discovered in the late 1970s and was originally known as leu-3 and T4 before being named CD4 in 1984. In humans, the CD4 protein is encoded by the CD4 gene.

<span class="mw-page-title-main">Tyrosin-protein kinase Lck</span> Lymphocyte protein

Tyrosin-protein kinase Lck is a 56 kDa protein that is found inside lymphocytes and encoded in the human by the LCK gene. The Lck is a member of Src kinase family (SFK) and is important for the activation of T-cell receptor (TCR) signaling in both naive T cells and effector T cells. The role of Lck is less prominent in the activation or in the maintenance of memory CD8 T cells in comparison to CD4 T cells. In addition, the constitutive activity of the mouse Lck homolog varies among memory T cell subsets. It seems that in mice, in the effector memory T cell (TEM) population, more than 50% of Lck is present in a constitutively active conformation, whereas less than 20% of Lck is present as active form in central memory T cells. These differences are due to differential regulation by SH2 domain–containing phosphatase-1 (Shp-1) and C-terminal Src kinase.

<span class="mw-page-title-main">Immunological synapse</span> Interface between lymphocyte and target cell

In immunology, an immunological synapse is the interface between an antigen-presenting cell or target cell and a lymphocyte such as a T cell, B cell, or natural killer cell. The interface was originally named after the neuronal synapse, with which it shares the main structural pattern. An immunological synapse consists of molecules involved in T cell activation, which compose typical patterns—activation clusters. Immunological synapses are the subject of much ongoing research.

<span class="mw-page-title-main">Interleukin 16</span> Protein-coding gene in the species Homo sapiens

Interleukin 16 is a pro-inflammatory pleiotropic cytokine. Its precursor, pro-interleukin-16 is a protein that in humans is encoded by the IL16 gene. This gene was discovered in 1982 at Boston University by Dr. David Center and Dr. William Cruikshank.

<span class="mw-page-title-main">CD86</span> Mammalian protein found in humans

Cluster of Differentiation 86 is a protein constitutively expressed on dendritic cells, Langerhans cells, macrophages, B-cells, and on other antigen-presenting cells. Along with CD80, CD86 provides costimulatory signals necessary for T cell activation and survival. Depending on the ligand bound, CD86 can signal for self-regulation and cell-cell association, or for attenuation of regulation and cell-cell disassociation.

Chemokine ligand 1 (CCL1) is also known as small inducible cytokine A1 and I-309 in humans. CCL1 is a small glycoprotein that belongs to the CC chemokine family.

<span class="mw-page-title-main">C-C chemokine receptor type 7</span> Protein-coding gene in the species Homo sapiens

C-C chemokine receptor type 7 is a protein that in humans is encoded by the CCR7 gene. Two ligands have been identified for this receptor: the chemokines ligand 19 (CCL19/ELC) and ligand 21 (CCL21). The ligands have similar affinity for the receptor, though CCL19 has been shown to induce internalisation of CCR7 and desensitisation of the cell to CCL19/CCL21 signals. CCR7 is a transmembrane protein with 7 transmembrane domains, which is coupled with heterotrimeric G proteins, which transduce the signal downstream through various signalling cascades. The main function of the receptor is to guide immune cells to immune organs by detecting specific chemokines, which these tissues secrete.

<span class="mw-page-title-main">C-C chemokine receptor type 6</span> Mammalian protein found in Homo sapiens

Chemokine receptor 6 also known as CCR6 is a CC chemokine receptor protein which in humans is encoded by the CCR6 gene. CCR6 has also recently been designated CD196. The gene is located on the long arm of Chromosome 6 (6q27) on the Watson (plus) strand. It is 139,737 bases long and encodes a protein of 374 amino acids.

<span class="mw-page-title-main">CD83</span> Human protein

CD83 is a human protein encoded by the CD83 gene.

<span class="mw-page-title-main">HLA-DMB</span> Protein-coding gene in the species Homo sapiens

HLA class II histocompatibility antigen, DM beta chain is a protein that in humans is encoded by the HLA-DMB gene.

<span class="mw-page-title-main">HLA-DMA</span> Protein-coding gene in the species Homo sapiens

HLA class II histocompatibility antigen, DM alpha chain is a protein that in humans is encoded by the HLA-DMA gene.

<span class="mw-page-title-main">HLA-DQA2</span> Protein-coding gene in the species Homo sapiens

HLA class II histocompatibility antigen, DQ(6) alpha chain is a protein that in humans is encoded by the HLA-DQA2 gene. Also known as HLA-DXA or DAAP-381D23.2, it is part of the human leukocyte antigen system.

<span class="mw-page-title-main">FGL2</span> Protein-coding gene in the species Homo sapiens

Fibrinogen-like protein 2, also known as FGL2, is a protein which in humans is encoded by the FGL2 gene.

<span class="mw-page-title-main">HAVCR2</span> Protein-coding gene in the species Homo sapiens

Hepatitis A virus cellular receptor 2 (HAVCR2), also known as T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), is a protein that in humans is encoded by the HAVCR2 (TIM-3) gene. HAVCR2 was first described in 2002 as a cell surface molecule expressed on IFNγ producing CD4+ Th1 and CD8+ Tc1 cells. Later, the expression was detected in Th17 cells, regulatory T-cells, and innate immune cells. HAVCR2 receptor is a regulator of the immune response.

<span class="mw-page-title-main">CD160</span> Protein found in humans

CD160 antigen is a protein that in humans is encoded by the CD160 gene.

Frédéric Triebel is a French immunologist who is best known for his 1990 discovery of the LAG3 immune control mechanism. Triebel worked through the 1990s in a collaboration between Institut Gustave Roussy and Merck Serono to establish LAG-3's mechanism of action in T cells and dendritic cells. In 2001 he founded Immutep SA, a biotech company, to develop the therapeutic potential of LAG3. In 2014 this company was acquired by Prima BioMed, where Triebel remains Chief Scientific and Medical Officer.

References

  1. 1 2 3 GRCh38: Ensembl release 89: ENSG00000089692 – Ensembl, May 2017
  2. 1 2 3 GRCm38: Ensembl release 89: ENSMUSG00000030124 – Ensembl, May 2017
  3. ↑ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ↑ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. 1 2 "Entrez Gene: LAG3 lymphocyte-activation gene 3".
  6. 1 2 3 Triebel F, Jitsukawa S, Baixeras E, Roman-Roman S, Genevee C, Viegas-Pequignot E, et al. (May 1990). "LAG-3, a novel lymphocyte activation gene closely related to CD4". The Journal of Experimental Medicine. 171 (5): 1393–405. doi:10.1084/jem.171.5.1393. PMC   2187904 . PMID   1692078.
  7. ↑ Mason D, André P, Bensussan A, Buckley C, Civin C, Clark E, et al. (Nov 2001). "CD antigens 2001". Journal of Leukocyte Biology. 70 (5): 685–90. doi: 10.1189/jlb.70.5.685 . PMID   11698486. S2CID   33478518.
  8. 1 2 3 Syn NL, Teng MW, Mok TS, Soo RA (December 2017). "De-novo and acquired resistance to immune checkpoint targeting". The Lancet. Oncology. 18 (12): e731–e741. doi:10.1016/s1470-2045(17)30607-1. PMID   29208439.
  9. 1 2 Triebel F, Jitsukawa S, Baixeras E, Roman-Roman S, Genevee C, Viegas-Pequignot E, et al. (May 1990). "LAG-3, a novel lymphocyte activation gene closely related to CD4". The Journal of Experimental Medicine. 171 (5): 1393–405. doi:10.1084/jem.171.5.1393. PMC   2187904 . PMID   1692078.
  10. 1 2 3 Huard B, Prigent P, Tournier M, Bruniquel D, Triebel F (Sep 1995). "CD4/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins". European Journal of Immunology. 25 (9): 2718–21. doi:10.1002/eji.1830250949. PMID   7589152. S2CID   25894632.
  11. 1 2 Workman CJ, Dugger KJ, Vignali DA (Nov 2002). "Cutting edge: molecular analysis of the negative regulatory function of lymphocyte activation gene-3". Journal of Immunology. 169 (10): 5392–5. doi: 10.4049/jimmunol.169.10.5392 . PMID   12421911.
  12. 1 2 Maeda TK, Sugiura D, Okazaki IM, Maruhashi T, Okazaki T (April 2019). "Atypical motifs in the cytoplasmic region of the inhibitory immune co-receptor LAG-3 inhibit T cell activation". The Journal of Biological Chemistry. 294 (15): 6017–6026. doi: 10.1074/jbc.RA119.007455 . PMC   6463702 . PMID   30760527.
  13. 1 2 Guy C, Mitrea DM, Chou PC, Temirov J, Vignali KM, Liu X, et al. (May 2022). "LAG3 associates with TCR-CD3 complexes and suppresses signaling by driving co-receptor-Lck dissociation". Nature Immunology. 23 (5): 757–767. doi:10.1038/s41590-022-01176-4. PMC   9106921 . PMID   35437325.
  14. 1 2 Takizawa F, Hashimoto K, Miyazawa R, Ohta Y, Veríssimo A, Flajnik MF, et al. (2023-12-21). "CD4 and LAG-3 from sharks to humans: related molecules with motifs for opposing functions". Frontiers in Immunology. 14: 1267743. doi: 10.3389/fimmu.2023.1267743 . PMC   10768021 . PMID   38187381.
  15. ↑ Ohashi K, Takizawa F, Tokumaru N, Nakayasu C, Toda H, Fischer U, et al. (August 2010). "A molecule in teleost fish, related with human MHC-encoded G6F, has a cytoplasmic tail with ITAM and marks the surface of thrombocytes and in some fishes also of erythrocytes". Immunogenetics. 62 (8): 543–559. doi:10.1007/s00251-010-0460-1. PMID   20614118. S2CID   12282281.
  16. 1 2 Grosso JF, Kelleher CC, Harris TJ, Maris CH, Hipkiss EL, De Marzo A, et al. (Nov 2007). "LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems". The Journal of Clinical Investigation. 117 (11): 3383–92. doi:10.1172/JCI31184. PMC   2000807 . PMID   17932562.
  17. ↑ Kim SS, Kim SH, Kang HS, Chung HY, Choi I, Cheon YP, et al. (Jan 2010). "Molecular cloning and expression analysis of pig lymphocyte activation gene-3 (LAG-3; CD223)". Veterinary Immunology and Immunopathology. 133 (1): 72–9. doi:10.1016/j.vetimm.2009.07.001. PMID   19631993.
  18. ↑ Huard B, Gaulard P, Faure F, Hercend T, Triebel F (January 1, 1994). "Cellular expression and tissue distribution of the human LAG-3-encoded protein, an MHC class II ligand". Immunogenetics. 39 (3): 213–7. doi:10.1007/bf00241263. PMID   7506235. S2CID   35247091.
  19. 1 2 Kisielow M, Kisielow J, Capoferri-Sollami G, Karjalainen K (Jul 2005). "Expression of lymphocyte activation gene 3 (LAG-3) on B cells is induced by T cells". European Journal of Immunology. 35 (7): 2081–8. doi: 10.1002/eji.200526090 . PMID   15971272. S2CID   12332458.
  20. 1 2 Workman CJ, Wang Y, El Kasmi KC, Pardoll DM, Murray PJ, Drake CG, et al. (Feb 2009). "LAG-3 regulates plasmacytoid dendritic cell homeostasis". Journal of Immunology. 182 (4): 1885–91. doi:10.4049/jimmunol.0800185. PMC   2675170 . PMID   19201841.
  21. ↑ Huard B, Tournier M, Hercend T, Triebel F, Faure F (December 1994). "Lymphocyte-activation gene 3/major histocompatibility complex class II interaction modulates the antigenic response of CD4+ T lymphocytes". European Journal of Immunology. 24 (12): 3216–21. doi:10.1002/eji.1830241246. PMID   7805750.
  22. 1 2 3 Workman CJ, Vignali DA (Apr 2003). "The CD4-related molecule, LAG-3 (CD223), regulates the expansion of activated T cells". European Journal of Immunology. 33 (4): 970–9. doi: 10.1002/eji.200323382 . PMID   12672063. S2CID   46053425.
  23. 1 2 Workman CJ, Cauley LS, Kim IJ, Blackman MA, Woodland DL, Vignali DA (May 2004). "Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo". Journal of Immunology. 172 (9): 5450–5. doi: 10.4049/jimmunol.172.9.5450 . PMID   15100286.
  24. 1 2 Huang CT, Workman CJ, Flies D, Pan X, Marson AL, Zhou G, et al. (Oct 2004). "Role of LAG-3 in regulatory T cells". Immunity. 21 (4): 503–13. doi: 10.1016/j.immuni.2004.08.010 . PMID   15485628.
  25. ↑ Wang J, Sanmamed MF, Datar I, Su TT, Ji L, Sun J, et al. (Jan 2019). "Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3". Cell. 176 (1–2): 334–47. doi:10.1016/j.cell.2018.11.010. PMC   6365968 . PMID   30580966.
  26. ↑ Blackburn SD, Shin H, Haining WN, Zou T, Workman CJ, Polley A, et al. (Jan 2009). "Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection". Nature Immunology. 10 (1): 29–37. doi:10.1038/ni.1679. PMC   2605166 . PMID   19043418.
  27. ↑ Andreae S, Piras F, Burdin N, Triebel F (Apr 2002). "Maturation and activation of dendritic cells induced by lymphocyte activation gene-3 (CD223)". Journal of Immunology. 168 (8): 3874–80. doi: 10.4049/jimmunol.168.8.3874 . PMID   11937541.
  28. ↑ Mao X, Gu H, Kim D, Kimura Y, Wang N, Xu E, et al. (May 2024). "Aplp1 interacts with Lag3 to facilitate transmission of pathologic α-synuclein". Nature Communications. 15 (1): 4663. doi:10.1038/s41467-024-49016-3. PMC   11143359 . PMID   38821932.
  29. ↑ "New Study Suggests Cancer Drug Could Be Used to Target Protein Connection That Spurs Parkinson's Disease". Johns Hopkins Medicine. 17 June 2024.
  30. ↑ "Oncology Pipeline at Immutep | Immunotherapy Treatment". www.immutep.com. Retrieved 2019-12-09.
  31. ↑ Avice MN, Sarfati M, Triebel F, Delespesse G, Demeure CE (March 1999). "Lymphocyte activation gene-3, a MHC class II ligand expressed on activated T cells, stimulates TNF-alpha and IL-12 production by monocytes and dendritic cells". Journal of Immunology. 162 (5): 2748–2753. doi: 10.4049/jimmunol.162.5.2748 . PMID   10072520. S2CID   24564488.
  32. 1 2 Clinical trial number NCT03704077 for "An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma" at ClinicalTrials.gov
  33. ↑ "Tesaro's Immuno-Oncology Platform". Tesaro web site.
  34. ↑ "Technology Platforms". Immutep LAG-3. Archived from the original on 1 July 2015. Retrieved 1 July 2015.
  35. ↑ A First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Intravenous (IV) Dose of GSK2831781 in Healthy Subjects and Patients With Plaque Psoriasis
  36. ↑ Baixeras E, Huard B, Miossec C, Jitsukawa S, Martin M, Hercend T, et al. (Aug 1992). "Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens". The Journal of Experimental Medicine. 176 (2): 327–37. doi:10.1084/jem.176.2.327. PMC   2119326 . PMID   1380059.
  37. ↑ Miyazaki T, Dierich A, Benoist C, Mathis D (May 1996). "LAG-3 is not responsible for selecting T helper cells in CD4-deficient mice". International Immunology . 8 (5): 725–9. doi: 10.1093/intimm/8.5.725 . PMID   8671660.
  38. ↑ Huard B, Mastrangeli R, Prigent P, Bruniquel D, Donini S, El-Tayar N, et al. (May 1997). "Characterization of the major histocompatibility complex class II binding site on LAG-3 protein". Proceedings of the National Academy of Sciences of the United States of America. 94 (11): 5744–9. Bibcode:1997PNAS...94.5744H. doi: 10.1073/pnas.94.11.5744 . PMC   20850 . PMID   9159144.
  39. ↑ Miyazaki T, Dierich A, Benoist C, Mathis D (Apr 1996). "Independent modes of natural killing distinguished in mice lacking Lag3". Science. 272 (5260): 405–8. Bibcode:1996Sci...272..405M. doi:10.1126/science.272.5260.405. PMID   8602528. S2CID   30676426.
  40. ↑ Huard B, Tournier M, Triebel F (Apr 1998). "LAG-3 does not define a specific mode of natural killing in human". Immunology Letters. 61 (2–3): 109–12. doi:10.1016/s0165-2478(97)00170-3. PMID   9657262.
  41. ↑ Annunziato F, Manetti R, Tomasévic I, Guidizi MG, Biagiotti R, Giannò V, et al. (May 1996). "Expression and release of LAG-3-encoded protein by human CD4+ T cells are associated with IFN-gamma production". FASEB Journal. 10 (7): 769–76. doi: 10.1096/fasebj.10.7.8635694 . PMID   8635694. S2CID   5807706.
  42. ↑ Annunziato F, Manetti R, Cosmi L, Galli G, Heusser CH, Romagnani S, et al. (Sep 1997). "Opposite role for interleukin-4 and interferon-gamma on CD30 and lymphocyte activation gene-3 (LAG-3) expression by activated naive T cells". European Journal of Immunology. 27 (9): 2239–44. doi:10.1002/eji.1830270918. PMID   9341765. S2CID   35524015.
  43. ↑ Scala E, Carbonari M, Del Porto P, Cibati M, Tedesco T, Mazzone AM, et al. (Jul 1998). "Lymphocyte activation gene-3 (LAG-3) expression and IFN-gamma production are variably coregulated in different human T lymphocyte subpopulations". Journal of Immunology. 161 (1): 489–93. doi: 10.4049/jimmunol.161.1.489 . PMID   9647260. S2CID   23898756.
  44. ↑ Bruniquel D, Borie N, Hannier S, Triebel F (Jul 1998). "Regulation of expression of the human lymphocyte activation gene-3 (LAG-3) molecule, a ligand for MHC class II". Immunogenetics. 48 (2): 116–24. doi:10.1007/s002510050411. PMID   9634475. S2CID   24657573.
  45. ↑ Hannier S, Tournier M, Bismuth G, Triebel F (Oct 1998). "CD3/TCR complex-associated lymphocyte activation gene-3 molecules inhibit CD3/TCR signaling". Journal of Immunology. 161 (8): 4058–65. doi: 10.4049/jimmunol.161.8.4058 . PMID   9780176. S2CID   21850137.
  46. ↑ Hannier S, Triebel F (Nov 1999). "The MHC class II ligand lymphocyte activation gene-3 is co-distributed with CD8 and CD3-TCR molecules after their engagement by mAb or peptide-MHC class I complexes". International Immunology. 11 (11): 1745–52. doi: 10.1093/intimm/11.11.1745 . PMID   10545478.
  47. ↑ Prigent P, El Mir S, Dréano M, Triebel F (Dec 1999). "Lymphocyte activation gene-3 induces tumor regression and antitumor immune responses". European Journal of Immunology. 29 (12): 3867–76. doi: 10.1002/(SICI)1521-4141(199912)29:12<3867::AID-IMMU3867>3.0.CO;2-E . PMID   10601994.
  48. ↑ Iouzalen N, Andreae S, Hannier S, Triebel F (Oct 2001). "LAP, a lymphocyte activation gene-3 (LAG-3)-associated protein that binds to a repeated EP motif in the intracellular region of LAG-3, may participate in the down-regulation of the CD3/TCR activation pathway". European Journal of Immunology. 31 (10): 2885–91. doi:10.1002/1521-4141(2001010)31:10<2885::AID-IMMU2885>3.0.CO;2-2. PMID   11592063. S2CID   26417417.
  49. ↑ Demeure CE, Wolfers J, Martin-Garcia N, Gaulard P, Triebel F (Sep 2001). "T Lymphocytes infiltrating various tumour types express the MHC class II ligand lymphocyte activation gene-3 (LAG-3): role of LAG-3/MHC class II interactions in cell-cell contacts". European Journal of Cancer. 37 (13): 1709–18. doi:10.1016/s0959-8049(01)00184-8. PMID   11527700.
  50. ↑ Workman CJ, Rice DS, Dugger KJ, Kurschner C, Vignali DA (Aug 2002). "Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3)". European Journal of Immunology. 32 (8): 2255–63. doi: 10.1002/1521-4141(200208)32:8<2255::AID-IMMU2255>3.0.CO;2-A . PMID   12209638.
  51. ↑ Andreae S, Buisson S, Triebel F (Sep 2003). "MHC class II signal transduction in human dendritic cells induced by a natural ligand, the LAG-3 protein (CD223)". Blood. 102 (6): 2130–7. doi: 10.1182/blood-2003-01-0273 . PMID   12775570.
  52. ↑ Li N, Workman CJ, Martin SM, Vignali DA (Dec 2004). "Biochemical analysis of the regulatory T cell protein lymphocyte activation gene-3 (LAG-3; CD223)". Journal of Immunology. 173 (11): 6806–12. doi: 10.4049/jimmunol.173.11.6806 . PMID   15557174.
  53. ↑ Di Carlo E, Cappello P, Sorrentino C, D'Antuono T, Pellicciotta A, Giovarelli M, et al. (Jan 2005). "Immunological mechanisms elicited at the tumour site by lymphocyte activation gene-3 (LAG-3) versus IL-12: sharing a common Th1 anti-tumour immune pathway". The Journal of Pathology. 205 (1): 82–91. doi: 10.1002/path.1679 . PMID   15586367. S2CID   25569191.
  54. ↑ Zhang Z, Duvefelt K, Svensson F, Masterman T, Jonasdottir G, Salter H, et al. (Mar 2005). "Two genes encoding immune-regulatory molecules (LAG3 and IL7R) confer susceptibility to multiple sclerosis". Genes and Immunity. 6 (2): 145–52. doi: 10.1038/sj.gene.6364171 . PMID   15674389.
  55. ↑ Lundmark F, Harbo HF, Celius EG, Saarela J, Datta P, Oturai A, et al. (Nov 2006). "Association analysis of the LAG3 and CD4 genes in multiple sclerosis in two independent populations". Journal of Neuroimmunology. 180 (1–2): 193–8. doi:10.1016/j.jneuroim.2006.08.009. PMID   17020785. S2CID   13944409.
  56. ↑ Maçon-Lemaître L, Triebel F (Jun 2005). "The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells". Immunology. 115 (2): 170–8. doi:10.1111/j.1365-2567.2005.02145.x. PMC   1782137 . PMID   15885122.
  57. ↑ Ausiello CM, Palazzo R, Spensieri F, Urbani F, Massari M, Triebel F, et al. (January 1, 2006). "Soluble CD30 and lymphocyte activation gene-3 (CD223), as potential serological markers of T helper-type cytokine response induced by acellular pertussis vaccine". International Journal of Immunopathology and Pharmacology. 19 (1): 97–104. doi:10.1177/205873920601900109. hdl: 11365/1220733 . PMID   16569347.
  58. ↑ Bayry J, Triebel F, Kaveri SV, Tough DF (Apr 2007). "Human dendritic cells acquire a semimature phenotype and lymph node homing potential through interaction with CD4+CD25+ regulatory T cells". Journal of Immunology. 178 (7): 4184–93. doi: 10.4049/jimmunol.178.7.4184 . PMID   17371975.
  59. ↑ Zhu X, Yang P, Zhou H, Li B, Huang X, Meng Q, et al. (Oct 2007). "CD4+CD25+Tregs express an increased LAG-3 and CTLA-4 in anterior chamber-associated immune deviation". Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht von Graefes Archiv für Klinische und Experimentelle Ophthalmologie. 245 (10): 1549–57. doi:10.1007/s00417-007-0591-8. PMID   17541623. S2CID   23556661.
  60. ↑ Grosso JF, Kelleher CC, Harris TJ, Maris CH, Hipkiss EL, De Marzo A, et al. (Nov 2007). "LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems". The Journal of Clinical Investigation. 117 (11): 3383–92. doi:10.1172/JCI31184. PMC   2000807 . PMID   17932562.
  61. ↑ Okamura T, Fujio K, Shibuya M, Sumitomo S, Shoda H, Sakaguchi S, et al. (Aug 2009). "CD4+CD25-LAG3+ regulatory T cells controlled by the transcription factor Egr-2". Proceedings of the National Academy of Sciences of the United States of America. 106 (33): 13974–9. Bibcode:2009PNAS..10613974O. doi: 10.1073/pnas.0906872106 . PMC   2729005 . PMID   19666526.
  62. ↑ Richter K, Agnellini P, Oxenius A (Jan 2010). "On the role of the inhibitory receptor LAG-3 in acute and chronic LCMV infection". International Immunology. 22 (1): 13–23. doi: 10.1093/intimm/dxp107 . hdl: 20.500.11850/15681 . PMID   19880580.
  63. ↑ Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, Beck A, Miller A, Tsuji T, et al. (Apr 2010). "Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer". Proceedings of the National Academy of Sciences of the United States of America. 107 (17): 7875–80. Bibcode:2010PNAS..107.7875M. doi: 10.1073/pnas.1003345107 . PMC   2867907 . PMID   20385810.
  64. ↑ Woo SR, Li N, Bruno TC, Forbes K, Brown S, Workman C, et al. (Jun 2010). "Differential subcellular localization of the regulatory T-cell protein LAG-3 and the coreceptor CD4". European Journal of Immunology. 40 (6): 1768–77. doi:10.1002/eji.200939874. PMC   2987677 . PMID   20391435.
  65. ↑ Camisaschi C, Casati C, Rini F, Perego M, De Filippo A, Triebel F, et al. (Jun 2010). "LAG-3 expression defines a subset of CD4(+)CD25(high)Foxp3(+) regulatory T cells that are expanded at tumor sites". Journal of Immunology. 184 (11): 6545–51. doi: 10.4049/jimmunol.0903879 . PMID   20421648.
  66. ↑ Lee KM, Baris D, Zhang Y, Hosgood HD, Menashe I, Yeager M, et al. (Aug 2010). "Common single nucleotide polymorphisms in immunoregulatory genes and multiple myeloma risk among women in Connecticut". American Journal of Hematology. 85 (8): 560–3. doi:10.1002/ajh.21760. PMC   2910184 . PMID   20568250.
  67. ↑ Lucas CL, Workman CJ, Beyaz S, LoCascio S, Zhao G, Vignali DA, et al. (May 2011). "LAG-3, TGF-β, and cell-intrinsic PD-1 inhibitory pathways contribute to CD8 but not CD4 T-cell tolerance induced by allogeneic BMT with anti-CD40L". Blood. 117 (20): 5532–40. doi:10.1182/blood-2010-11-318675. PMC   3109721 . PMID   21422469.
  68. ↑ Hemon P, Jean-Louis F, Ramgolam K, Brignone C, Viguier M, Bachelez H, et al. (May 2011). "MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis". Journal of Immunology. 186 (9): 5173–83. doi: 10.4049/jimmunol.1002050 . PMID   21441454.
  69. ↑ Bettini M, Szymczak-Workman AL, Forbes K, Castellaw AH, Selby M, Pan X, et al. (Oct 2011). "Cutting edge: accelerated autoimmune diabetes in the absence of LAG-3". Journal of Immunology. 187 (7): 3493–8. doi:10.4049/jimmunol.1100714. PMC   3178660 . PMID   21873518.
  70. ↑ Butler NS, Moebius J, Pewe LL, Traore B, Doumbo OK, Tygrett LT, et al. (Feb 2012). "Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection". Nature Immunology. 13 (2): 188–95. doi:10.1038/ni.2180. PMC   3262959 . PMID   22157630.
  71. ↑ Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, et al. (Feb 2012). "Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape". Cancer Research. 72 (4): 917–27. doi:10.1158/0008-5472.CAN-11-1620. PMC   3288154 . PMID   22186141.
  72. ↑ Cho H, Chung YH (Aug 2012). "Construction, and in vitro and in vivo analyses of tetravalent immunoadhesins". Journal of Microbiology and Biotechnology. 22 (8): 1066–76. doi:10.4014/jmb.1201.01026. PMID   22713982.
  73. ↑ Gagliani N, Magnani CF, Huber S, Gianolini ME, Pala M, Licona-Limon P, et al. (Jun 2013). "Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells". Nature Medicine. 19 (6): 739–46. doi:10.1038/nm.3179. PMID   23624599. S2CID   21305032.
  74. ↑ Sega EI, Leveson-Gower DB, Florek M, Schneidawind D, Luong RH, Negrin RS (January 27, 2014). "Role of lymphocyte activation gene-3 (Lag-3) in conventional and regulatory T cell function in allogeneic transplantation". PLOS ONE. 9 (1): e86551. Bibcode:2014PLoSO...986551S. doi: 10.1371/journal.pone.0086551 . PMC   3903521 . PMID   24475140.
  75. ↑ Peña J, Jones NG, Bousheri S, Bangsberg DR, Cao H (Jun 2014). "Lymphocyte activation gene-3 expression defines a discrete subset of HIV-specific CD8+ T cells that is associated with lower viral load". AIDS Research and Human Retroviruses. 30 (6): 535–41. doi:10.1089/AID.2012.0195. PMC   4046223 . PMID   24180338.
  76. ↑ Camisaschi C, De Filippo A, Beretta V, Vergani B, Villa A, Vergani E, et al. (Jul 2014). "Alternative activation of human plasmacytoid DCs in vitro and in melanoma lesions: involvement of LAG-3". The Journal of Investigative Dermatology. 134 (7): 1893–902. doi: 10.1038/jid.2014.29 . PMID   24441096.
  77. ↑ Bae J, Lee SJ, Park CG, Lee YS, Chun T (Sep 2014). "Trafficking of LAG-3 to the surface on activated T cells via its cytoplasmic domain and protein kinase C signaling". Journal of Immunology. 193 (6): 3101–12. doi: 10.4049/jimmunol.1401025 . PMID   25108024.
  78. ↑ Okamura T, Sumitomo S, Morita K, Iwasaki Y, Inoue M, Nakachi S, et al. (February 19, 2015). "TGF-β3-expressing CD4+CD25(-)LAG3+ regulatory T cells control humoral immune responses". Nature Communications. 6 (6329): 6329. Bibcode:2015NatCo...6.6329O. doi:10.1038/ncomms7329. PMC   4346620 . PMID   25695838.
  79. ↑ Phillips BL, Mehra S, Ahsan MH, Selman M, Khader SA, Kaushal D (Mar 2015). "LAG3 expression in active Mycobacterium tuberculosis infections". The American Journal of Pathology. 185 (3): 820–33. doi:10.1016/j.ajpath.2014.11.003. PMC   4348466 . PMID   25549835.
  80. ↑ Chu KH, Chiang BL (May 2015). "Characterization and functional studies of forkhead box protein 3(-) lymphocyte activation gene 3(+) CD4(+) regulatory T cells induced by mucosal B cells". Clinical and Experimental Immunology. 180 (2): 316–28. doi:10.1111/cei.12583. PMC   4408166 . PMID   25581421.

Further reading

This article incorporates text from the United States National Library of Medicine, which is in the public domain.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.